CHMP adopts positive opinion for Kymriah in relapsed or refractory follicular lymphoma

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

FDA approved an oral combination of Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

May 15, 2026

Vol.52 No.19

Drugs & Targets

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA approved Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease

FDA has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediateor high-risk myelofibrosis; adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease or chronic GVHD after failure of one or two lines of systemic therapy.

May 08, 2026

Vol.52 No.18

Guest Editorial

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

Cancer survivorship in the United States now tops 18 million people. That is a lot of people walking around with a shared experience, and yet somehow we barely talk about what surviving cancer actually does to you.

April 24, 2026

Vol.52 No.16

By Edward Miskie

Drugs & Targets

FDA approves Tecartus for r/r mantle cell lymphoma

FDA granted full approval to Tecartus (brexucabtagene autoleucel), Kite’s CAR T-cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

FDA granted approval of Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult and pediatric patients 12 years and older with previously untreated Stage 3 or 4 classical Hodgkin Lymphoma.

March 27, 2026

Vol.52 No.12

CHMP adopts positive opinion for Kymriah in relapsed or refractory follicular lymphoma

YOU MAY BE INTERESTED IN

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

FDA approves Tecartus for r/r mantle cell lymphoma

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login